Eli Lilly's Humalog Receives Confirmation of Continued Marketing Authorization in Europe from EMA
Maintaining Humalog's Marketing Authorization Status and Regulatory Significance in the European Market
The European Medicines Agency (EMA) has officially confirmed the marketing authorization status of Humalog (insulin lispro), a rapid-acting insulin analog from Eli Lilly. This decision is based on decades of accumulated clinical efficacy and safety data since its initial approval in Europe in April 1996, demonstrating the continued suitability of the product for market supply. Humalog, which acts as an insulin receptor agonist, has firmly established itself as an essential medicine for rapidly controlling postprandial blood glucose levels in patients with diabetes. The continued authorization, following rigorous quality monitoring by regulatory authorities, represents a significant regulatory milestone in ensuring the stability of the global supply chain and access to treatment for patients.
Defending the Original Drug Amidst Biosimilar Competition
Following the expiration of Humalog's patent, numerous biosimilar competitors, including Insulin lispro Sanofi from Sanofi, have entered the European market. In this highly competitive environment, the continued renewal of Humalog's marketing authorization by the EMA is a critical prerequisite for defending its market share. Eli Lilly has strengthened its competitiveness by diversifying its portfolio, including the approval in July 2014 of Humalog 200 units/ml (a formulation with a doubled drug concentration). This continued regulatory approval plays a significant role in maintaining the trust of existing patients and securing stable prescription patterns by addressing the market entry barriers of new entrants.
Financial Contribution of a Blockbuster Insulin and the Size of the Global Diabetes Market
According to Eli Lilly's financial reports, Humalog generated annual revenues of USD 2.325 billion in 2024 and USD 1.040 billion in the first half of 2025, making it a key blockbuster drug. Given that the global insulin market is a massive USD 20 billion to USD 33 billion, Humalog's share remains significant. This achievement has been made amidst fierce competition from global competitors such as Novo Nordisk's NovoRapid (insulin aspart) and Sanofi's Apidra (insulin glulisine). Ultimately, the EMA's continued marketing authorization is a driving force behind Eli Lilly's ability to consistently secure billions of dollars in stable revenue annually across Europe.
Enhanced Regulatory Transparency and Increased Trust Among Healthcare Professionals and Patients with Diabetes
The EMA's update of the European Public Assessment Report (EPAR) and confirmation of the marketing authorization are measures to maximize transparency in drug safety management. Healthcare professionals and patients can now directly access reliable drug information and clinical safety data through official regulatory reports. Precise quality control of insulin formulations is critical in diabetes treatment, as it directly affects patient safety, and regulatory approval is a decisive factor in increasing prescription confidence. In particular, the fact that the target molecule, insulin receptor agonist activity, has been reconfirmed to be maintained consistently over a long period is expected to have a positive impact on patients' long-term treatment planning.
This approval signifies that Eli Lilly (LLY) is solidifying its position as an original drug manufacturer in the global insulin market, which is a massive market exceeding USD 20 billion. Humalog, a blockbuster drug with USD 2.325 billion in revenue in 2024, has secured a foundation to maintain its competitive edge in the European market against strong competitors such as Novo Nordisk's NovoRapid and Sanofi's Apidra through this authorization renewal. In the medium to long term, this is an example of demonstrating business resilience by diversifying its portfolio and renewing regulatory qualifications to generate stable cash flow amidst the ongoing onslaught of biosimilars following patent expiration. Furthermore, the long-term safety data of insulin lispro, the active ingredient of the drug, has been re-recognized by regulatory authorities, providing a valuable contribution by offering reliable clinical standard indicators to diabetes researchers.
Source: EMA (ema)